8-K: Tempest Therapeutics Halts At-The-Market Equity Offering Program

Tempest Therapeutics, Inc. announced the suspension and termination of its prospectus supplement related to its at-the-market (ATM) equity offering program with Jefferies LLC, effective June 11, 2025.

Summary

• Tempest Therapeutics, Inc. (the "Company") delivered written notice to Jefferies LLC on June 11, 2025, to suspend and terminate the prospectus supplement dated February 6, 2025.
• This prospectus supplement was related to the Company's common stock, par value $0.001 per share, issuable under the Open Market Sale AgreementSM dated June 20, 2024, with Jefferies.
• The Company will not make any further sales of its securities through this specific Sales Agreement unless a new prospectus, prospectus supplement, or registration statement is filed.
• The underlying Sales Agreement itself, dated June 20, 2024, remains in full force and effect, meaning the framework for future ATM offerings is still in place, but the current authorization to sell under the specific prospectus supplement is terminated.

Sentiment

Score: 7

Explanation: The suspension of an ATM offering, while removing a funding source, often signals that the company either has sufficient capital for the near term or believes its stock is undervalued, thus avoiding dilution at current prices. This is generally viewed positively by existing shareholders.

Positives

• Suspension of the ATM prospectus supplement removes the immediate threat of equity dilution for existing shareholders.
• May indicate that the company has sufficient cash reserves or is pursuing alternative, less dilutive financing options.
• Could signal management's confidence in the current stock valuation, choosing not to sell shares at current prices.

Negatives

• Removes a flexible and readily available source of capital for the company.
• Could imply that market conditions were not favorable for equity sales, or that the company was unable to raise capital at desired terms through the ATM.

Future Outlook

The Company will not make any sales of its securities pursuant to the Sales Agreement, unless and until a new prospectus, prospectus supplement or a new registration statement is filed.

Industry Context

At-the-market (ATM) offerings are a common financing tool for biotech companies, allowing them to raise capital opportunistically by selling shares directly into the market at prevailing prices. Suspending such a program can be a strategic decision based on market conditions, cash needs, or alternative financing plans.

Stakeholder Impact

• Shareholders: Reduced immediate risk of dilution from new equity issuance.
• Creditors: No direct impact mentioned, but could indirectly affect future liquidity if alternative funding is not secured.

Next Steps

• The Company will not make any sales of its securities pursuant to the Sales Agreement, unless and until a new prospectus, prospectus supplement or a new registration statement is filed.

Key Dates

Keywords

Tempest Therapeutics, TPST, SEC filing, 8-K, ATM offering, equity financing, prospectus, dilution, capital raise, Jefferies LLC, biotechnology, pharmaceuticals, common stock